MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
109.05
-0.62 (-0.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close109.67
Open109.50
Bid108.46 x 800
Ask0.00 x 1000
Day's Range108.82 - 109.79
52 Week Range81.66 - 111.24
Volume3,039,663
Avg. Volume4,478,681
Market Cap146.309B
Beta (3Y Monthly)0.49
PE Ratio (TTM)33.44
EPS (TTM)3.26
Earnings DateNov 19, 2019
Forward Dividend & Yield2.16 (1.97%)
Ex-Dividend Date2019-09-26
1y Target Est117.39
Trade prices are not sourced from all markets
  • GlobeNewswire

    Medtronic Introduces Envision™ Pro Continuous Glucose Monitoring (CGM) System in Europe

    Medtronic plc (MDT), the global leader in medical technology, services and solutions, today announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system — a fully disposable, zero calibration professional CGM system — has obtained CE (Conformité Européenne) Mark approval. Medtronic will begin commercial release in Europe and the Middle East this fall, subject to local regulatory requirements1. This new technology will empower healthcare professionals and their patients with either type 1 and type 2 diabetes to see accurate glucose levels and trends over time to develop more optimal diabetes therapy plans.

  • GlobeNewswire

    Medtronic Announces Robotic-Assisted Surgery Investor Update

    Medtronic plc (MDT), the global leader in medical technology, today announced that it will host aRobotic-Assisted Surgery (RAS) Investor Update on Tuesday, September 24, 2019, in Hartford, Conn., from 2:00 p.m. to approximately 5:30 p.m. Eastern Daylight Time. The update will include a robotic-assisted surgical procedure performed in a lab as part of the Medtronic Minimally Invasive Therapy Group’s ongoing development and testing process of its RAS technology. In addition, the update will include remarks and responses to audience questions from a panel of surgeons and Medtronic management.

  • Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
    Zacks

    Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International

    Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International

  • GlobeNewswire

    National Osteoporosis Foundation Supports New Evidence-Based Care Pathway Designed to Optimize Care for Vertebral Compression Fractures (VCF)

    Medtronic plc (MDT), the global leader in medical technology, today announced that the National Osteoporosis Foundation (NOF) supports the VCF Care Pathway, a new evidence-based clinical care pathway developed by a multispecialty panel of experts to ensure osteoporotic vertebral compression fracture (VCF) patients receive timely and appropriate care. The VCF Care Pathway, published in Spine Journal in 20181and developed with grant support from Medtronic*, is an algorithm that has the potential to be integrated into a hospital’s electronic medical record (EMR) system, ensuring patients who present with moderate or severe back pain as their primary or secondary complaint receive standardized treatment across all departments and healthcare providers, consisting of evidence-based care and follow-up.

  • Medtronic (MDT) Earns Dow Jones Sustainability Recognition
    Zacks

    Medtronic (MDT) Earns Dow Jones Sustainability Recognition

    Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.

  • BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
    Zacks

    BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal

    This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.

  • Why You Should Invest in Dividend Growth Stocks
    Zacks

    Why You Should Invest in Dividend Growth Stocks

    The appeal for dividend ETFs has been rising on investors' drive for juicy yields and consistent income amid heightened uncertainty and volatility.

  • Medtronic Hits Our Price Target: Time to Take Profits?
    TheStreet.com

    Medtronic Hits Our Price Target: Time to Take Profits?

    Back in early June we reviewed the charts and indicators of Medtronic, Inc. and we wrote that "In this Point and Figure chart of MDT, below, we can see a $108 price target but trades at $98.39 and $99.37 are needed to confirm the uptrend." Those trades happened and prices reached our target last month and pushed a little higher recently. In the updated daily candlestick chart of MDT, below, we can see an upper shadow above $110 showing that the new price area was rejected. The On-Balance-Volume (OBV) line shows a small double top and small bearish divergence as prices made a new high but the OBV line did not.

  • A Note On Medtronic plc's (NYSE:MDT) ROE and Debt To Equity
    Simply Wall St.

    A Note On Medtronic plc's (NYSE:MDT) ROE and Debt To Equity

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • GlobeNewswire

    Medtronic and Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes

    DUBLIN and BAGSVÆRD, Denmark, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT), and Novo Nordisk A/S today announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic, such as the Guardian™ Connect system. People with diabetes spend an average of one hour a day on self-care, amounting to a full two years devoted exclusively to their disease over their lifetime.1,2This new, non-exclusive collaboration reflects both companies′commitment to making diabetes management easier by integrating key health technologies.

  • GlobeNewswire

    Medtronic Named a Leading Sustainability Company

    Medtronic plc (MDT) today announced that it has been recognized as one of the world's leading companies for sustainability with its inclusion in the Dow Jones Sustainability North America Index (DJSI North America) for the twelfth consecutive year. The DJSI North America includes a select group of companies based on their performance across a variety of sustainability criteria, including economic performance, environmental stewardship, social responsibility, and corporate governance. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the FTSE4Good Index Series.

  • Medtronic (MDT) Soars to 52-Week High, Time to Cash Out?
    Zacks

    Medtronic (MDT) Soars to 52-Week High, Time to Cash Out?

    Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Is Medtronic (MDT) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Medtronic (MDT) Outperforming Other Medical Stocks This Year?

    Is (MDT) Outperforming Other Medical Stocks This Year?

  • IoMT Becomes the Buzzword in New Age MedTech Investing
    Zacks

    IoMT Becomes the Buzzword in New Age MedTech Investing

    Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.

  • 3D Printing Gaining Popularity: 3 MedTech Stocks to Watch
    Zacks

    3D Printing Gaining Popularity: 3 MedTech Stocks to Watch

    In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.

  • GuruFocus.com

    Medtronic Plc (MDT) EVP & Group President Diabetes Hooman Hakami Sold $8.9 million of Shares

    EVP & Group President Diabetes of Medtronic Plc (30-Year Financial, Insider Trades) Hooman Hakami (insider trades) sold 82,877 shares of MDT on 09/10/2019 at an average price of $107.31 a share. Continue reading...

  • Here’s who America’s CEOs are backing in the Democratic presidential race
    MarketWatch

    Here’s who America’s CEOs are backing in the Democratic presidential race

    Nineteen chief executive officers of S&P 500 companies so far have given their own money to 2020 Democratic White House hopefuls.

  • United Therapeutics' Trevyent NDA for PAH Accepted by FDA
    Zacks

    United Therapeutics' Trevyent NDA for PAH Accepted by FDA

    United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.

  • 5 High-Flying Stocks Near 52-Week High That Can Scale Higher
    Zacks

    5 High-Flying Stocks Near 52-Week High That Can Scale Higher

    Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

  • Bruker (BRKR) Introduces the nanoIR3-s Broadband System
    Zacks

    Bruker (BRKR) Introduces the nanoIR3-s Broadband System

    The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.

  • ETFs to Gain as Surgical Robots Rise in Popularity
    Zacks

    ETFs to Gain as Surgical Robots Rise in Popularity

    We highlight ETFs which are set to gain from an expanding surgical robotic market on factors like growing demand for automation in healthcare, rising cases of chronic diseases and ageing population.

  • GNC Holdings Rides on New Pacts Amid Weak Same Store Sales
    Zacks

    GNC Holdings Rides on New Pacts Amid Weak Same Store Sales

    GNC Holdings' (GNC) recent joint venture with vitamins and nutritional supplement manufacturer International Vitamin Corporation shows high prospects at present.

  • Medtronic's (MDT) MiniMed 670G Gains German Reimbursement
    Zacks

    Medtronic's (MDT) MiniMed 670G Gains German Reimbursement

    Medtronic's (MDT) MiniMed 670G is witnessing a solid uptake in the United States ever since its launch last year.

  • Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well
    Zacks

    Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well

    The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.

  • Illumina Banks on New Product Suite Despite Margin Woes
    Zacks

    Illumina Banks on New Product Suite Despite Margin Woes

    The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.